Background: Diffuse intrinsic pontine gliomas have poor prognosis.
Observation: We report on 2 patients with diffuse intrinsic pontine glioma treated with radiation, followed by temozolamide 200 mg/m2/d for 5 days every 28 days and bevacizumab 10 mg/kg/dose every 14 days. Both patients have ongoing PFS of 37 and 47 months from diagnosis. A decrease in tumor size by >65% was observed in both the patients. Both patients continue treatment. No steroid requirement since 10 weeks after radiation. Quality of life is excellent and the chemotherapy regimen is well tolerated.
Conclusions: A clinical trial in an expanded cohort is warranted to determine the toxicity and evaluate response.
*Aflac Center for Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta, Emory University School of Medicine
†Department of Radiology, Children’s Healthcare of Atlanta
‡Department of Radiation Oncology, Winship Cancer Center Institute of Emory University, Atlanta, GA
The authors declare no conflict of interest.
Reprints: Tobey J. MacDonald, MD, Aflac Center for Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta, Emory University School of Medicine, 2015 Uppergate Drive, #442, Atlanta, GA 30322 (e-mail: firstname.lastname@example.org).
Received September 6, 2011
Accepted July 13, 2012